OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $586,000 Stake in Mersana Therapeutics, Inc. (NASDAQ:MRSN)

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its position in Mersana Therapeutics, Inc. (NASDAQ:MRSN) by 28.1% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 410,029 shares of the company’s stock after selling 160,000 shares during the period. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Mersana Therapeutics were worth $586,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in MRSN. Millennium Management LLC increased its position in shares of Mersana Therapeutics by 206.4% during the fourth quarter. Millennium Management LLC now owns 795,973 shares of the company’s stock worth $1,138,000 after acquiring an additional 536,190 shares in the last quarter. Jacobs Levy Equity Management Inc. grew its stake in Mersana Therapeutics by 12.0% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 1,111,998 shares of the company’s stock valued at $1,590,000 after purchasing an additional 118,952 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new position in Mersana Therapeutics during the fourth quarter worth $65,000. BNP Paribas Financial Markets increased its stake in shares of Mersana Therapeutics by 52.3% during the 4th quarter. BNP Paribas Financial Markets now owns 361,147 shares of the company’s stock worth $516,000 after purchasing an additional 123,949 shares during the last quarter. Finally, 683 Capital Management LLC increased its position in Mersana Therapeutics by 392.4% during the fourth quarter. 683 Capital Management LLC now owns 900,000 shares of the company’s stock worth $1,287,000 after buying an additional 717,207 shares during the last quarter. 93.92% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

MRSN has been the topic of several research analyst reports. William Blair started coverage on shares of Mersana Therapeutics in a research report on Thursday, February 6th. They issued an “outperform” rating on the stock. Wedbush reissued an “outperform” rating and issued a $3.00 target price (down previously from $4.00) on shares of Mersana Therapeutics in a research report on Tuesday, May 6th. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Mersana Therapeutics presently has a consensus rating of “Buy” and an average price target of $3.67.

Mersana Therapeutics Stock Down 0.7%

Shares of MRSN opened at $0.36 on Wednesday. The company has a current ratio of 2.35, a quick ratio of 2.35 and a debt-to-equity ratio of 13.35. Mersana Therapeutics, Inc. has a 12 month low of $0.26 and a 12 month high of $2.88. The firm’s 50 day moving average is $0.38 and its 200-day moving average is $1.04. The stock has a market capitalization of $44.64 million, a PE ratio of -0.59 and a beta of 1.32.

Mersana Therapeutics (NASDAQ:MRSN) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.05. The firm had revenue of $16.36 million for the quarter, compared to analyst estimates of $7.71 million. Mersana Therapeutics had a negative return on equity of 401.37% and a negative net margin of 214.20%. Equities research analysts forecast that Mersana Therapeutics, Inc. will post -0.62 EPS for the current year.

About Mersana Therapeutics

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.